New Analysis of Original RECORD Trial Concludes Avandia is Safe

Drug Industry Daily
A A
A much-talked-about re-adjudication of GlaxoSmithKline's controversial RECORD trial of Avandia reaffirms its original findings that the drug does not boost cardiovascular risk, the company says.

To View This Article:

Login

Subscribe To Drug Industry Daily